FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma.
The mRNA cancer vaccine is here! FDA grants BioNTech Fast Track qualification for mRNA cancer vaccine for the treatment of advanced melanoma.
On November 19, 2021, mRNA vaccine giant BioNTech issued an announcement announcing that the US FDA has granted its mRNA cancer vaccine BNT111 fast track qualification .
BNT111 is an investigational cancer immunotherapy for the treatment of advanced melanoma.
It is one of the four product candidates of BioNTech’s FixVac platform. The platform uses a combination of tumor-associated antigens encoded by mRNA to trigger powerful and precise cancer Immune response to cancer treatment .
The BNT111 vaccine is currently undergoing phase 2 clinical trials for the treatment of PD-1 inhibitor refractory/relapsed unresectable stage III or IV melanoma, clinical trial number: NCT04526899.
It is reported that BNT111 encodes four tumor-associated antigens that appear in more than 90% of melanoma patients- NY-ESO-1 , MAGE-A3 , tyrosinase and TPTE , which can be prevented by combining with PD-1 inhibitors Depletion of T cells improves the prognosis of patients with advanced melanoma.
Fast Track aims to promote the development and review of new drugs and vaccines designed to treat or prevent serious diseases that may solve unmet medical needs.
The FDA’s approval this time is based on existing preclinical and clinical data. On July 29, 2020, BioNTech published the interim analysis of the Phase 1 clinical trial in Nature , showing that BNT111 has the potential to overcome the currently inoperable advanced melanin The limitations of the tumor.
BioNTech co-founder and chief medical officer Özlem Türeci said that BNT111’s fast track approval by the FDA demonstrates the potential of the FixVac platform.
With the support of the FDA, BioNTech will accelerate the further development of the BNT111 project to provide life-threatening and difficult-to-treat melanoma patients New treatment options.
Reference materials:
https://www.nature.com/articles/s41586-020-2537-9
https://investors.biontech.de/news-releases/news-release-details/biontech-receives-fda-fast-track-designation-its-fixvac
FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
